Biora Therapeutics Shares Rise 64% After FDA Clears Application for Ulcerative Colitis Treatment
By Ben Glickman
Shares of Biora Therapeutics rose late Thursday after the company received clearance from the U.S. Food and Drug Administration to use its ulcerative colitis treatment in a clinical trial.
The stock was up 64% to $2.03 in after-hours trading, following a 2.5% rise at Thursday's close. Shares were down 62% this year as of the close.
The San Diego-based biotechnology company said the FDA had approved its investigational new drug application for BT-600, a drug and device combination used to treat moderate to severe ulcerative colitis.
The company said it would complete the activities required by the FDA and the trial site before enrolling subjects in its first trial in the coming weeks.
An IND allows a company to use an investigational drug in humans in a clinical study.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 30, 2023 18:38 ET (23:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom